Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or Clonal Cytopenia of Undetermined Significance

• Status: Recruiting
• Trial end date: 2024-03-15

Summary

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory) or clonal cytopenia of undetermined significance. Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells.

• Phase: Phase 2

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Cancer Institute (NCI)
• Treatments: Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Ascorbic Acid; BB 1101; Carboplatin; Cisplatin; Cytarabine; Dexamethasone; Dexamethasone acetate; Etoposide; Etoposide phosphate; Gemcitabine; Ifosfamide; Immunoglobulins; Isophosphamide mustard; Oxaliplatin; Podophyllotoxin; Rituximab; Vitamins